Ou Bai, Md/phd
Clinical trials sponsored by Ou Bai, Md/phd, explained in plain language.
-
Targeted combo aims at tough lymphoma subtype
Disease control Not yet recruitingThis phase 2 trial tests whether adding the targeted drug orelabrutinib to standard chemotherapy improves outcomes for people with a specific genetic subtype of diffuse large B-cell lymphoma (MCD subtype). Participants receive the drug combination during initial treatment, follow…
Phase: PHASE2 • Sponsor: Ou Bai, MD/PHD • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC
-
New hope for lymphoma patients who fail standard therapies
Disease control Not yet recruitingThis study tests a drug called pirtobrutinib in 40 people with mature B-cell lymphoma whose cancer has worsened or who cannot tolerate other BTK inhibitor drugs. Participants take one pill daily. Researchers will measure how many patients respond, how long the response lasts, and…
Sponsor: Ou Bai, MD/PHD • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC